Julià Gotzens Bersch

Dr. Julià Gotzens Bersch

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
JBJulià Gotzens Bersch
Julià Gotzens Bersch
ACAina Colom-Balañà
Aina Colom-Balañà
MMManuel Monsonis
Manuel Monsonis
LALaia Alsina
Laia Alsina
MRMaría Antonia Ruiz-Cobo
María Antonia Ruiz-Cobo
Silvia Simó NebotSilvia Simó Nebot
Silvia Simó Nebot
Background/Objectives: Children and adolescents with haematologic malignancies or other causes of immunosuppression are at high risk of severe infections. Determining the probability of Gram-negative bacilli bloodstream infections (GNB-BSI) within 24 h of blood culture (BC) incubation could support early antibiotic de-escalation, compared to the current guidelines recommending de-escalation after 48–72 h. Methods: Retrospective, observational single-centre study describing BC time-to-positivity (TTP) in GNB-BSI in a paediatric cohort of immunocompromised children. Results: In 128 episodes (100 patients), TTP was less than 24 h in >95% cases. TTP did not differ based on sex, underlying disease, degree of neutropenia, or PICU admission. Antibiotic initiation prior to BC collection and microbiological aetiology (microbiological aetiology different from Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae) were the only identified risk factors associated with BC growth beyond 24 h. No patients with late BC growth died or required PICU admission. Conclusions: If BC remains negative after 24 h of incubation, GNB-BSI is unlikely in immunocompromised children and adolescents with fever. These results support early de-escalation strategies, shortening unnecessary exposure to broader-spectrum antibiotics, and potentially decreasing adverse events and costs.

22 September 2026 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
AFAlfonso Maria Farina
Alfonso Maria Farina
CPClara Larraya Palacios
Clara Larraya Palacios
LLLaura Florit Lluch
Laura Florit Lluch
MEMarina Pons Espinal
Marina Pons Espinal
LRLaia Baleta Riera
Laia Baleta Riera
JBJulià Gotzens Bersch
Julià Gotzens Bersch
Was not provided for this article.

10 September 2026 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
CCCristina Cámara Costa
Cristina Cámara Costa
APAres Benavent Puiggené
Ares Benavent Puiggené
NMNuria Mas Malagarriga
Nuria Mas Malagarriga
MRMaría Antonia Ruiz-Cobo
María Antonia Ruiz-Cobo
IMIrene Martínez-De-Albeniz
Irene Martínez-De-Albeniz
Silvia Simó NebotSilvia Simó Nebot
Silvia Simó Nebot
Background: Maintaining broad-spectrum antibiotics until resolution of fever and recovery of absolute neutrophil count (ANC) has traditionally been the standard approach for pediatric patients with cancer and for hematopoietic stem-cell transplantation (HSCT) recipients who present with febrile neutropenia (FN). Recent studies in adults support the safety of discontinuing empiric antibiotic treatment (EAT) prior to ANC recovery. However, data in children remain limited. Methods: Retrospective study that included patients under 18 years of age with cancer and/or undergoing HSCT admitted with FN between June 2022 and August 2023, in whom EAT was discontinued prior to ANC ≥500/mm3. Patients already receiving antibiotics for a documented or suspected source of bacterial infection, sepsis, or admitted to pediatric intensive care unit (PICU) were excluded. We report the characteristics and clinical outcomes (readmission, new fever onset, and new infection) within 7 days of the discontinuation of EAT, as well as the 30-day PICU admission, infection-related mortality, and all-cause mortality rates. Findings: We included 97 episodes (65 patients) of FN, 47 (48.4%) occurred in children with hematologic disease (malignant or non-malignant), including patients who had received an HSCT (n = 8) and/or a chimeric antigen receptors T-cell therapy (n = 6). Fever lasted less than 24 h in 75.3% of episodes. Median EAT duration was 3 days (interquartile range [IQR]: 3-5). Absolute neutrophil count recovery occurred at a median of 4 days (IQR 2-12) after EAT discontinuation. Fever recurred in 11 episodes (11.3%) within 7 days from EAT discontinuation. An infectious cause was identified in 3/11 episodes (mild bacterial folliculitis, probable primary Cytomegalovirus infection, and invasive fungal infection, n = 1 each). No admissions to PICU or 30-day infection-related mortality were observed. Two patients died because of non-infectious causes. Conclusion: Early EAT discontinuation before ANC recovery in selected pediatric patients with FN, including high-risk patients, may reduce hospitalization and antibiotic exposure.

30 September 2026 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
GMGeorgina Morón-Cazalilla
Georgina Morón-Cazalilla
MPMarina Pons-Espinal
Marina Pons-Espinal
AAAnna Alonso-Saladrigues
Anna Alonso-Saladrigues
LALaura Arqués
Laura Arqués
NSNazaret Sánchez-Sierra
Nazaret Sánchez-Sierra
ANAntoni Noguera-Julian
Antoni Noguera-Julian
Background: BK virus–associated hemorrhagic cystitis (BKV-HC) is well recognized after hematopoietic stem-cell transplantation but remains poorly described in nontransplanted children with hematological malignancies. Observations: We retrospectively identified 6 children with leukemia or lymphoma who developed BKV-HC over a 17-year period. Dysuria and macroscopic hematuria were the most common manifestations. One patient developed urinary obstruction and acute kidney injury. Median symptom duration was 16 days. Most patients received supportive care, and all but one recovered completely without sequelae. Conclusions: BKV-HC is an uncommon complication in nontransplanted children receiving chemotherapy for hematological malignancies. Clinical outcomes are generally favorable with conservative management.